雄激素剥脱治疗后前列腺癌发展为去势抵抗性前列腺癌的分子机制

Molecular mechanisms of castration-resistant prostate cancer progressed from prostate cancer by androgen deprivation treatment

雄激素剥脱治疗（ADT）是局部晚期或转移性激素敏感性前列腺癌患者治疗的金标准。然而，大多数患者经过数月或数年的ADT治疗，病情却通过一系列不同的分子机制发展为去势抵抗性前列腺癌（CRPC）。CRPC目前仍是不可治愈的，而且极具致命性。因此，深入研究不同分子机制在CRPC发生发展中的作用，可能为未来进行相关靶向治疗指引新方向。

Androgen deprivation treatment （ADT） is the gold standard of care for patients with locally advanced or metastatic hormone-sensitive prostate cancer. However, most of these patients have developed to the castration-resistant prostate cancer （ CRPC ） after months or years through a series of different molecular mechanisms during ADT. So far, CRPC is still incurable and deadly, therefore, it is very important for researchers to study different molecular mechanism in the occurrence and development of CRPC, which may provide some new directions for targeted therapy.